Page 1594 - Small Animal Internal Medicine, 6th Edition

1566 Index

Mast cell tumors Mentation, abnormal, 1074 Milbemycin, 386t–388t, 515t–517t Murmurs (Continued)
biologic behavior of, 1329–1330 Meperidine, 629t–630t description of, 203 congenital heart disease as cause of,
in cats, 1333–1334 Merck. see Finasteride dosage of, 444t continuous (machinery), 9–11, 10f
100
VetBooks.ir cutaneous, 1333 Mesalamine, 441, 515t–517t Milk of Magnesia. see Magnesium decrescendo, 9–10, 10f
Meropenem, 1437t–1438t
clinicopathologic findings, 1328–1329
nasal mites treated with, 263
in degenerative atrioventricular valve
dermoepidermal, 1329f, 1333
hydroxide
Mesangial cells, 675, 676f
description of, 1263f, 1290t
disease, 122
diagnosis of, 1330–1331, 1331f Mesenchymal tissue, 1259 Milk thistle, 590–591 diastolic, 9, 11
Mineral oil, 346
Mesenchymal tumors, 1260–1261
disseminated, 1332–1333 Mesenteric lymphadenopathy, 1299f Mineralocorticoids, 883–884, 887 ejection, 9–10
in dogs, 1328–1333 Mesenteric torsion, 499 Minipress. see Prazosin functional, 9–11
epidemiology of, 1328 Mesothelioma, 186, 513–514 Minocycline, 1437t–1438t grading, 10t
etiology of, 1328 Mestinon. see Pyridostigmine Minute virus, pregnancy loss and, 966 holosystolic, 9–10, 10f, 114
prognosis for, 1331–1333 Metabolic acidosis Mirtazapine, 515t–517t innocent, 9, 100
staging of, 1332t in acute kidney injury, 691 Misoprostol, 439t, 440, 515t–517t, 960 in kittens, 101f
treatment of, 1331–1333, 1332t bicarbonate therapy for, 844–845 Mites, nasal, 253f, 263 mitral insufficiency, 285
ulceration and, 470 in chronic kidney disease, 697 Mitotane, 872–875, 874b. see also “musical,”, 9
Masticatory muscle myositis (MMM), Metabolic alkalosis, hypochloremic- o,p’DDD nonpathologic, 9–11
451, 1091f, 1174–1175, 1175f, 1252 hypokalemic, 465–466 Mitral dysplasia in patent ductus arteriosus, 103
Mastitis, 978–979, 979f, 1441t Metabolic encephalopathies, 1074 description of, 112 phonocardiographic configuration of,
Mastocytoma, 1328 Metabolic epidermal necrosis, 615 dog breeds affected by, 102t 9–10, 10f
Maternal behavior, inappropriate, Metabolic myopathies, 1178–1179, 1181 radiographic findings, 103t physiologic, 10–11
974–975, 975f Metabolic storage diseases, 1153–1154 Mitral insufficiency, 11 presystolic, 9
Maternal bonding, 974–975 Metabolism disorders echocardiographic findings, 124f in pulmonary hypertension, 115
Mean electrical axis, 45 hyperlipidemia. see Hyperlipidemia murmurs associated with, 285 in puppies, 101f
Meclizine, 1185t–1186t obesity. see Obesity radiographic findings, 123f “regurgitant,”, 9–10
Medetomidine, 49b polyphagia with weight loss, 898–899, Mitral regurgitation systolic, 9–11
Median nerve, 1158t 899t in cats, 159 systolic ejection, 11
Mediastinal lymphomas, 1294, 1496 Metacam. see Meloxicam in dogs, 17f to-and-fro, 11
Mediastinal masses, 377–378, 377f Metaldehyde, 1099b echocardiographic findings, 125f–126f, Muscle atrophy, 1047
anterior, 1290 Metamucil. see Psyllium 144f Muscle biopsy, 1073
approach to, 1290–1293 Metarubricytosis, 1345t in restrictive cardiomyopathy, 168 Muscle size, 1047
cytological characteristics of, 1292f Metastatic cancer, 1289–1290, 1290t Mitral valve Muscle spasms, in tetanus, 1182
description of, 360, 366 Metered-dose inhaler (MDI), 327–328, echocardiography for, 26, 27f Muscle tone
fine-needle aspiration of, 1291 332f enlargement of, 125f involuntary alterations in, 1181–1183
radiographic findings, 1291f Methadone, 629t–630t Mitral valve motion, 26, 27f in screening neurologic examination,
types of, 1290t Methicillin-resistant Staphylococcus M-mode echocardiography, 22–27 1047
Mediastinum, radiography of, 365–366 aureus, 1539 atrial fibrillation on, 81f Muscular dystrophy, 1179
Medical adrenalectomy, 874 Methimazole, 794, 796t, 896t–897t dilated cardiomyopathy on, 144f Musculocutaneous nerve, 1158t
Medical history, 3–4, 3b Methocarbamol, 1185t–1186t measurements on, 23–27 Musculoskeletal disorders, 1023–1025,
Medium-chain triglycerides (MCTs), 435 Methotrexate, 1204t, 1209t–1210t, 1305 mitral valve motion, 26, 27f 1024f
Medulla, 1037–1038 Methoxyflurane, 49b normal values for, 23–27, 25t Musculoskeletal system, 134b
Mefoxin. see Cefoxitin Methylprednisolone acetate, 386t–388t, patent ductus arteriosus findings, Myasthenia gravis, 1042, 1169–1172,
Megaesophagus 515t–517t, 1222t 103–104, 105f 1171f, 1171b, 1250–1251, 1251t
acquired, 455 Methylprednisolone sodium succinate, pericardial effusion findings, 179–180, Mycobacterium spp.
in dysautonomia, 456 1133–1134, 1185t–1186t 179f culture of, 1431
hypoadrenocorticism and, 885 Methylxanthines views on, 23, 24f M. avium, 1259f, 1429–1430
regurgitation caused by, 346 in cats, 327b Mobitz type I atrioventricular block, Mycophenolate mofetil, 1225t,
upright feeding for animals with, in dogs, 327b 43–44 1227–1228, 1251t, 1255t–1256t
1171f Metoclopramide, 438, 440–441, 455–456, Mobitz type II atrioventricular block, Mycoplasma spp., 1440t
Megakaryocytes, 1395 515t–517t 43–44 antibiotics for, 1441t, 1446
Melanoma prolactin release controlled using, 978 Modified Karnovsky performance score, clinical findings of, 1465
cytologic findings, 1262f reproductive uses of, 1034t–1036t 1266t diagnosis of, 1465–1466
metastasis of, 1290t Metoprolol Modified transudate pleural fluid, epidemiology of, 1464–1465
Melarsomine dihydrochloride in cats, 90t–91t 361–363 etiology of, 1464–1465
administration of, 199 characteristics of, 94t, 95 Monoclonal gammopathies, 1421–1422, M. canis, 1465–1466
heartworm disease treated with, 199, in dogs, 90t–91t 1421b M. cynos, 321
199b dosage of, 90t–91t Monoclonal hyperglobulinemia, 1415 M. felis, 1465
Melatonin, 749, 896t–897t Metronidazole, 444t, 515t–517t Monocytosis, 1377–1378, 1378b, M. haemofelis, 1211
Melena, 402–403, 403b bacterial infections treated with, 1426t nasal cultures for, 255
Meloxicam, 1197t, 1209t–1210t, 1268t 1437t–1438t Mononuclear-phagocytic cells, 1407 polyarthritis caused by, 1199
Membranoproliferative joint disease treated with, 1209t–1210t Monoparesis, 1045t prevention of, 1466
glomerulonephritis, 678, 693b toxicity caused by, 1116 Morphine, 62b, 386t–388t treatment of, 1466
Membranous glomerulonephritis, 678 Metronomic chemotherapy, 1273–1274 for acute pancreatitis, 628–631 zoonotic aspects of, 1466
Menace response, 1055, 1056f, 1084, Mexiletine, 83–84 analgesic uses of, 227b Mycoplasmal bronchitis, 329t
1085f, 1085b adverse effects of, 92 dosage of, 1134t Mycosis fungoides, 1295–1296,
Meninges, 134b in cats, 90t–91t stress relief using, 380t 1296f
Meningiomas, 1081, 1145 in dogs, 90t–91t Motility modifiers, 440–441 Mycotic infections, 1128
Meningitis, 1117–1129 dosage of, 90t–91t Mucopurulent nasal discharge, 240–241, antifungal drugs for, 1504t
canine eosinophilic, 1122 pharmacokinetics of, 92 241b, 1444 blastomycosis. see Blastomycosis
general considerations in, 1117 Microalbuminuria, 662 Mucosal lesions, 389 coccidioidomycosis, 1505–1507
parasitic, 1129 Microangiopathic hemolysis, 1322 Mucous membranes, 4–5, 5b cryptococcosis. see Cryptococcosis
steroid-responsive meningitis-arteritis, Microbiology, male fertility and, color of, 284 histoplasmosis, 1510–1511
1118f, 1119, 1119b 997–1001, 998f, 999t–1000t, 1000f Multicat households, obesity and, nasal. see Nasal mycoses
Meningoencephalitis Microcardia, 885 906 polysystemic, 1502–1513
canine eosinophilic, 1122 Microcytosis, 1345t Multicentric lymphoma, 1294, 1295f, Mydriasis, 1086
clotrimazole treatment as cause of, 263 Microfilaricides, for heartworm disease, 1496 Myelinosis, 919
distemper, 1125 207–208 Multidrug-resistant infections, 443 Myelitis, 1117
parasitic, 1129 Microthrombosis, 1404 Multimodal environmental Myelodysplastic syndromes, 1312–1313,
Meningoencephalomyelitis Microvascular dysplasia, 610–611 modifications, 727–728, 728b 1355b, 1385–1386
bacterial, 1123–1124 Micturition Multinodular adenomatous hyperplasia, Myelofibrosis, 1355b, 1386, 1386f
granulomatous, 1064, 1087–1088, anatomy of, 730, 731f 788 Myelography, 1064–1065, 1065f–1066f,
1120–1121, 1121b disorders of, 730–737 Multiorgan failure, 621 1137, 1138f
necrotizing, 1121–1122 drugs that affect, 733t–734t Multiple myeloma, 654t–655t Myelomalacia, 1140–1141
toxoplasmosis as cause of, 1126 neurologic control of, 1042–1043 Murmurs Myelophthisis, 1355b, 1385
of unknown etiology, 1119–1120 physiology of, 730 auscultation of, 9–11, 10f, 10t Myeloproliferative disease, 1311
Mental state, 1043 Mifepristone, 960 characteristics of, 7 Myelosuppression, 1280